$CVSI CV Sciences, Inc. to Host Webcast on its CBD-based Drug Development Program on November 10, 2016
Marketwired October 28, 2016
LAS VEGAS, NV--(Marketwired - October 28, 2016) - CV Sciences, Inc. (CVSI) (the "Company") today announced that it will hold a webcast on Thursday, November 10, 2016 at 5:00PM Eastern Standard Time to discuss its drug development program and specifically its drug candidate utilizing synthetically-formulated CBD for use in treatment of smokeless tobacco addiction. According to Statista, there were approximately $5.3 billion in retail sales of smokeless tobacco products in 2014, and approximately 1.3 billion units of smokeless tobacco products sold during that time. Smokeless tobacco addiction is a huge unmet medical need, as there are currently no FDA-approved drugs to treat this widespread and deadly addiction. The current treatment market in the U.S. alone is estimated at greater than $2 billion.
The webcast will discuss the Company's initial drug candidate (CVSI-007), which is a chewing gum that combines synthetic CBD and nicotine.
The Company will provide details on webcast access by press release on Thursday, November 3, 2016.
About CV Sciences, Inc.
CV Sciences, Inc. operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and distributing botanical-based CBD products to a range of market sectors. CV Sciences, Inc. has p
AI
